Last reviewed · How we verify
Placebo(for Telmisartan 80mg)
Placebo is an inert substance with no active pharmacological mechanism.
Placebo is an inert substance with no active pharmacological mechanism. Used for Control arm in Phase 3 clinical trial for Telmisartan 80mg (hypertension).
At a glance
| Generic name | Placebo(for Telmisartan 80mg) |
|---|---|
| Sponsor | IlDong Pharmaceutical Co Ltd |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Placebo serves as a control comparator in clinical trials and contains no active pharmaceutical ingredient. It is used to establish the baseline efficacy and safety profile of the active drug (Telmisartan 80mg) by comparison. Any observed effects are attributed to natural disease progression, patient expectation, or other non-pharmacological factors.
Approved indications
- Control arm in Phase 3 clinical trial for Telmisartan 80mg (hypertension)
Common side effects
Key clinical trials
- A Randomized, Double-blind, Multi-center, Active-controlled, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of THP-00101, THP-00102, and THP-00103 in Subjects With T2DM and Essential Hypertension (PHASE3)
- Efficacy & Safety Study of YH22162 vs Telmisartan/Amlodipine in Patients With Hypertension Inappropriately Controlled on Telmisartan/Amlodipine Treatment (PHASE3)
- Improving 24-hour Blood Pressure in Obstructive Sleep Apnea (EARLY_PHASE1)
- Telmisartan as an Adjunctive Treatment for Metabolic Problems in Patients With Schizophrenia (PHASE4)
- Telmisartan+Amlodipine Fixed Dose Combination in Hypertension (PHASE3)
- PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes (PHASE4)
- Efficacy and Safety of Telmisartan/Rosuvastatin Co-administration in Hypertensive Patients With Hyperlipidemia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo(for Telmisartan 80mg) CI brief — competitive landscape report
- Placebo(for Telmisartan 80mg) updates RSS · CI watch RSS
- IlDong Pharmaceutical Co Ltd portfolio CI